Security key
68232V884
Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW)
CUSIP: 68232V884
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, par value $0.01 per share
- Total 13F shares
- 3,418,588
- Total 13F value
- $3,863,003
- Share change
- +1,351,193
- SEC-reported price per share
- $1.13
- Number of holders
- 21
- Value change
- +$1,409,923
- Number of buys
- 12
- Number of sells
- 7
- Shares outstanding
- 16,062,541
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
21
Top holders
10
TRAW full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Traws Pharma, Inc. SEC filings
Traws Pharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 68232V884
Recent filing periods:
Ownership snapshot
Top reported holders of TRAW - Traws Pharma, Inc. - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ikarian Capital, LLC
Disclosed value leader
Ikarian Capital, LLC
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
Lead comparable stake: 10%
13D/G row: Ikarian Capital, LLC
Showing 1-6 of 15 holder rows.
Quick read
Ikarian Capital, LLC leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ikarian Capital, LLC's linked filing trail.
Comparable ownership
Top 5
Ikarian Capital, LLC
10%
Alyeska Investment Group, L.P.
9.9%
Adage Capital Management, L.P.
9.1%
Ayrton Capital LLC
4.3%
ORBIMED ADVISORS LLC
3.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ikarian Capital, LLC |
13D/G
13F
Company
|
10%
|
$1,308,164
812,524 shares
|
+$359,065 | 31 Dec 2025 |
| Alyeska Investment Group, L.P. |
13D/G
|
9.9%
|
$462,446
302,252 shares
|
$0 | 31 Dec 2024 |
| Adage Capital Management, L.P. |
13D/G
|
9.1%
|
$1,175,300
730,000 shares
|
+$644,000 | 31 Dec 2025 |
| Ayrton Capital LLC |
13D/G
|
4.3%
|
$552,125
342,935 shares
|
-$97,751 | 31 Dec 2025 |
| ORBIMED ADVISORS LLC |
13F
Company
|
3.8%
|
$1,120,232
605,531 shares
|
— | 30 Sep 2025 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
2.1%
|
$610,500
330,000 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
21
Shares
3,418,588
Rows available
21
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
18
Q4 2025 holders
21
Holder diff
3
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend